TEXAS, February 23, 2021 / PRNewswire / – Matica Biotechnology, Inc. (Bio Matica), a contract development and manufacturing organization (CDMO) specializing in the clinical and commercial production of cell and gene therapies, today ceremonially inaugurated its new 25,000 sq. ft. facility that will house its GMP virus production suites, development laboratories and research offices. companies. The new building will be located in Providence Park at 2501 Earl Rudder Freeway in College Station.
The inauguration ceremony is scheduled for Tuesday, February 23 at the 10:00 am. College Station Mayor Karl Mooney attended the event, along with members of the College Station City Council, Bryan Mayor Andrew Nelson, Bryan-College Station Chamber President / CEO of Commerce Glen Brewer, Chairman of the Board of Brazos Valley EDC Mike Gentryand Brazos Valley EDC President / CEO Matt Prochaska.
“Global demand for virus products continues to exceed production capacity in accordance with strict Good Manufacturing Practices or GMPs required by regulatory agencies for human use,” said Matica Bio CEO Dr. Byung Se So. “Our new facility will help close that gap by establishing state-of-the-art, modular virus production clean rooms, integrated with the latest vector technologies to maximize speed, flexibility and efficiency throughout our customers’ product development cycle. ”
Dr. So continued, “The Vale do Brazos area, including College Station, is fast becoming one of the most important biotechnology centers in the country, and it was an easy decision for our company to settle here. The availability of a qualified workforce, together with the influence of the Texas A&M University System, will support the level of rapid job growth that we expect over the next few years. “
Mr. Timothy Lutz, Matica Bio’s The Manufacturing Director commented: “Matica Biotecnologia is excited to establish our operations here in College Station. We seek to be an active part of our community and look forward to hiring several local professionals, both for the construction and operational phases. We are planning to use state-of-the-art equipment, processes and materials to enter a new class of CDMOs “
“We are honored to welcome Matica Biotechnology in the Vale do Brazos, as they strive to manufacture solutions to the health challenges of today and tomorrow,” said the President / CEO of Brazos Valley Economic Development Corporation Matt Prochaska. “A hallmark of our region is its legacy of solving problems that the world faces, and Matica Bio’s arrival advances this again. Working with your team in the United States and South Korea it was a pleasure and we offer the resources and experience of our community to help them succeed and grow. “
Matica Bio’s The GMP facility is scheduled to open in the third quarter of 2021, using a bioreactor-based platform, with access to GMP’s production slots from the beginning of 2022.
About Matica Biotechnology, Inc.
Bio Matica, an affiliate of CHA Biotech, provides viral vector GMP manufacturing services for cell and gene therapies, vaccines, oncolytic vectors and other advanced therapy products. Our GMP facility in College Station, TX was designed for rapid development, scaling and production of Lentivirus and AAV products for clinical delivery. Bio Matica offers process development, production, product launch and stability assessment of viral vector products; together with the quality supervision and regulatory guidance necessary to ensure the success of our customers.
About CHA Biotech
CHA Biotech is a global biotechnology company with subsidiaries in Korea and abroad. We develop cell therapy products, including stem cells, umbilical cord blood and NK cells. The CHA Biotech network develops and produces essential drugs for incurable diseases and includes CMG Pharmaceutical, CHA Vaccine Institute, CHA Meditech, Seoul CRO, Solidus Investment and Matica Biotechnology.
CHA Biotech, together with CHA University, the CHA Comprehensive Research Institute and hospitals in 61 locations in 7 countries, develops and expands a unique model that integrates research institutes, commercial biotechnology and hospital systems to provide intensive basic research, rapid clinical testing and effective in conjunction with development and manufacturing capabilities.
SOURCE Matica Biotechnology, Inc.